Alcon’s AcrySof Intraocular Lens Reaches 100 Million Implants

October 12, 2017: By Jon Swedien

AlconAlcon announced Sept. 29 that its AcrySof intraocular lenses (IOLs) have been implanted more than 100 million times.

In celebration, Alcon launched its “100 Million Moments Made” campaign, which includes resources designed to showcase the accomplishment in markets around the globe, the Fort Worth, Texas, company said.

The first recorded implantation of an AcrySof IOL was in the UK in 1990. Since then, the platform has grown to include solutions for correcting astigmatism (AcrySof IQ Toric) and presbyopia (AcrySof IQ ReSTOR and PanOptix), Alcon said.

The AcrySof family of IOLs includes brands available in approximately 120 markets: AcrySof IQ, AcrySof IQ Toric, AcrySof IQ ReSTOR, AcrySof IQ ReSTOR Toric, AcrySof IQ PanOptix, and AcrySof IQ PanOptix Toric.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Imprimis Offers Compounded Alternative to Restasis for Dry Eye

US District Court Invalidates Four Restasis Patents

BioTime Prices $25 Million Public Offering of Common Stock

Gemini Completes $42.5 Million Series A Financing for Dry AMD Treatment

BIOPHYTIS Raises €10.4 Million to Develop Anti-Aging Drugs, One for Dry AMD

Amydis Receives $530 Thousand NIH Award to Advance Ophthalmic Diagnostic Probes

Realm Announces Completion of $26 million Private Placement

Sight Sciences Secures $10 Million in Oversubscribed Series C Financing

Aerpio Names Stephen Hoffman CEO; Founder Joseph Gardner Remains President

FDA Advisory Panel Recommends Aerie’s Rhopressa for Glaucoma Patients

FDA Panel Unanimously Backs Spark’s Luxturna as Retinal Gene Therapy

PanOptica Secures $11 Million to Advance Topical Anti-VEGF Eye Drop for Neovascular AMD

Nicox and pSivida to Collaborate to Develop a Sustained Release Drug to Lower IOP

Azura Nets $16 Million in Series B Funding for Dry Eye Treatment

Alcon’s AcrySof Intraocular Lens Reaches 100 Million Implants

Notal Vision’s ForeseeHome Reaches Milestone of 3 Million Tests

FDA to Review Spark’s Retinal Gene Therapy Candidate Oct. 12

Alcon’s AutonoMe IOL Injector Gains CE Mark Approval

Shire Sues Allergan, Claiming Bundling Tactics Block Restasis Competitors

Allergan Decries ‘Unfair’ Patent Challenge Process as US House Launches Probe of Tribe Deal

Coming soon

2017 Refractive Surgery Report: A Global Market Analysis for 2016 to 2022